Remove Drugs Remove Metabolic Stability Remove Small Molecule
article thumbnail

Metabolism of 2022 FDA approved small molecule drugs PART 2

Metabolite Tales Blog

Metabolism of 2022 FDA approved small molecule drugs part 2 Mixing it Up By Julia Shanu-Wilson In Part 1 of this topic we looked at metabolism of the small molecule drugs approved by the FDA in 2022 that were mediated by CYP3A4.

article thumbnail

The Data-Driven Future of Drug Development

DrugBank

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Game-changing pan-TEAD inhibitor for solid tumours

Drug Target Review

This molecule shows immense potential as a pan-TEAD inhibitor, targeting advanced solid tumours. TEAD proteins are crucial for tumour progression and drug resistance, making them an attractive focus for therapeutic interventions. The novel molecules were further ranked based on their ADME and selectivity profiles.

article thumbnail

Breaking C-F bonds in drugs

Metabolite Tales Blog

Breaking C-F bonds in drugsmetabolism mediated release of fluorine By Samuel Coe and Julia Shanu-Wilson Lenacapavir, recently approved for multi-drug resistant HIV-1 infection, contains 10 fluorine atoms. Increasingly used in drug design, some drug structures are now bristling with fluorine atoms.

Drugs 52
article thumbnail

N-glucuronidation: the human element

Metabolite Tales Blog

N -glucuronidation: the human element By Julia Shanu-Wilson In our last blog of the year, we look at why N -glucuronidation of drugs is important in human drug metabolism. Glucuronidation is the most common phase II reaction observed in the metabolism of drugs in humans.

article thumbnail

AI in Drug Discovery 2023 - A Highly Opinionated Literature Review (Part I)

Practical Cheminformatics

Review articles 2023 was a bit of a mixed bag for AI in drug discovery. Benchmarking Generated Poses: How Rational is Structure-based Drug Design with Generative Models [link] 1.4 How accurately can one predict drug binding modes using AlphaFold models? Docking, protein structure prediction, and benchmarking II.

Drugs 143